

Applicants : David J. Pinsky
Serial No. : 09/374,586
Filed : August 13, 1999
Page 3

In The Claims

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1-38. (Canceled)

39. (Previously Presented) A method for treating or preventing stroke in a human subject susceptible to intracerebral hemorrhaging, comprising administering to the human subject an effective amount of a CD39 polypeptide comprising consecutive amino acids the sequence of which is set forth in SEQ ID NO:2 so as to inhibit adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate catabolism without increasing incidence of intracerebral hemorrhage in the human subject.

40-41. (Canceled)

42. (Previously Presented) The method of claim 39, wherein the administration of the CD39 polypeptide occurs at the onset of stroke in the subject.

43. (Previously Presented) The method of claim 39, wherein the administration of the CD39 polypeptide is prior to stroke onset in the subject.

44. (Previously Presented) The method of claim 39, wherein the administration of the CD39 polypeptide occurs after the onset of stroke in the subject.

45. (Previously Presented) The method of claim 39, wherein the CD39 polypeptide is administered in a dosage of 1-20 mg/kg of the subject's body weight.

Applicants : David J. Pinsky
Serial No. : 09/374,586
Filed : August 13, 1999
Page 4

46. (Previously Presented) The method of claim 39, wherein the CD39 polypeptide is administered in a dosage of 4-8 mg/kg of the subject's body weight.